希美加群 T17265

Product Introduction
Bioactivity


英文名: Ximelagatran

描述: Ximelagatran (H 376-95) 是一种口服活性凝血酶抑制剂，可选择性的、竞争性的抑制游离和凝块结合的凝血酶。它是一种抗凝药物，具有快速起效的抗凝作用，可预测的，剂量依赖性的药代动力学和药效学。

体外活性: Ximelagatran is an orally administered direct thrombin inhibitor under development as an anticoagulant agent for prophylaxis against and treatment of thromboembolism. Ximelagatran is rapidly absorbed and quickly converted into its active form Melagatran which is a reversible, active-site inhibitor of both free and clot-bound thrombin that has stable and reproducible pharmacokinetic properties. Initial studies have shown Ximelagatran to have good efficacy and safety in the prevention of venous thromboembolism after total knee or total hip replacement[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 55 mg/ml (116.14 mM)
H2O : Insoluble


关键字: Inhibitor | inhibit | Thrombin | Ximelagatran

相关产品: Heparin | Pirodomast | RS-601 | Thrombin receptor peptide ligand | RWJ-445167 | NFPS | Edoxaban Tosylate Monohydrate | Edoxaban | Hirullin P18 | Heparin sodium salt

相关库: Drug Repurposing Compound Library | ReFRAME Related Library | Drug-induced Liver Injury (DILI) Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Human Metabolite Library | Inhibitor Library | Protease Inhibitor Library | Anti-Cardiovascular Disease Compound Library | NO PAINS Compound Library

希美加群 T17265信息由TargetMol中国为您提供，如您想了解更多关于希美加群 T17265报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途